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People frequently live for many years with multiple chronic
conditions (multimorbidity) that impair health outcomes and are
expensive to manage. Multimorbidity has been shown to reduce
quality of life and increase mortality. People with multimorbidity
also rely more heavily on health and care services and have
poorer work outcomes. Musculoskeletal disorders (MSDs) are
ubiquitous in multimorbidity because of their high prevalence,
shared risk factors, and shared pathogenic processes amongst
other long-term conditions. Additionally, these conditions
signiﬁcantly contribute to the total impact of multimorbidity,
having been shown to reduce quality of life, increase workc.uk (S.J. Dufﬁeld), b.ellis@arthritisresearchuk.org (B.M. Ellis), ngoodson@
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(2017), https://doi.org/10.1016/j.berh.2017disability, and increase treatment burden and healthcare costs.
For people living with multimorbidity, MSDs could impair the
ability to cope and maintain health and independence, leading to
precipitous physical and social decline. Recognition, by health
professionals, policymakers, non-proﬁt organisations, and
research funders, of the impact of musculoskeletal health in
multimorbidity is essential when planning support for people
living with multimorbidity.
© 2017 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The co-existence of at least two different long-term health conditions in the same individual has
been variously deﬁned in the literature as ‘multimorbidity’ or ‘co-morbidity’ but with a lack of clear
consensus about the use of these deﬁnitions [1]. The term ‘comorbidity’ is generally used for any
additional health condition(s) occurring at the same time in the same individual as a previously
deﬁned index condition. For the purpose of this review, multimorbidity has been deﬁned as any in-
dividual having two or more long-term conditions. For example, a person with concomitant diabetes
and asthma has ‘multimorbidity’. Importantly, these terms include long-term mental, as well as
physical component health conditions. However deﬁned, there is evidence that the prevalence of
people living with two or more long-term health conditions is rising [2].
Musculoskeletal disorders (MSDs) appear to form a principal component of certain multimorbidity
clusters [3] and are common in multimorbidity [4,5]. Certainly, a substantial proportion of people with
MSDs now live with multimorbidity [4,6]. There are many MSDs, including inﬂammatory rheumatic
diseases, such as rheumatoid arthritis and spondyloarthritis; degenerative conditions, such as osteo-
arthritis; fragility conditions, such as osteoporosis; and regional pain syndromes, such as low back pain,
neck pain and, the widespread pain condition, ﬁbromyalgia. MSDs are common throughout the life
course but become increasingly common at older ages (in particular, low back pain and osteoarthritis).
This review sets out what we know about the importance of MSDs in multimorbidity, informed by
the work done by the leading UK charity for people with MSDs, Arthritis Research UK [7], and a search
of the literature. Our aim is to highlight the importance of multimorbidity andmusculoskeletal disease
to healthcare commissioners, healthcare providers, government and policymakers, and non-proﬁt
organisations to ensure that the complex needs of this growing group of people are appropriately
addressed and to inform the research agenda.
The importance of musculoskeletal conditions in multimorbidity
MSDs are markedly heterogeneous, ranging from highly disabling but fortunately less common
conditions such as rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus to
considerably more common but generally less disabling conditions such as low back pain and osteo-
arthritis. At older ages, osteoporosis also causes a substantial burden by increasing the risk of low-
trauma fractures [8].
In addition, multimorbidity and co-morbidity are deﬁnedwith inconsistent criteria in the literature.
Multimorbidity has been described as having co-occurring long-term conditions; co-occurring long-
term conditions or acute conditions; or co-occurring long-term conditions, acute conditions or health-
related risk factors [9,10]. Studies may also use completely different checklists of speciﬁc diseases or
health-related risk factors. These difﬁculties with classiﬁcation cause a particular problemwhen trying
to deﬁne the prevalence of multimorbidity [11].
As a consequence, it is also difﬁcult to deﬁne the impact of MSDs in multimorbidity. Furthermore,
impact can be measured in a number of different ways: on an individual, on an individual's family/
carers, society, healthcare resources and costs. Complete data are not available for each of the MSDs inld SJ, et al., The contribution of musculoskeletal disorders in
and policy, Best Practice & Research Clinical Rheumatology
.09.004
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patchy. Nevertheless, the following sections outline what we currently know about the relative
importance of MSDs in multimorbidity.
Musculoskeletal diseases are a pervasive component of multimorbidity
Multimorbidity can occur for a number of reasons [12]. Chieﬂy, the existing high prevalence of
certain conditions implies that the likelihood of co-occurrence together in one person, by chance
alone, is high, particularly for conditions which become more common with increasing age. For
example, osteoarthritis and asthma may commonly co-occur but have no known etiological asso-
ciation. Shared risk factors between conditions can also increase the likelihood of clustering. For
example, obesity increases the risk of both osteoarthritis and type 2 diabetes [13,14]. Finally,
sometimes a pathogenic link between conditions means the risk of another developing is greater. For
example, there is a known causal pathway between rheumatoid arthritis and cardiovascular disease
[15]. Below we outline how these three mechanisms of multimorbidity relate to the prevalence of
MSDs in multimorbidity.MSDs and multimorbidity are both highly prevalent
Longitudinal evidence from various countries suggests that the number of people with multi-
morbidity is growing [2,16,17]. In the European Union, there is an estimated 50 million people with
multimorbidity, and this number is expected to grow as the population ages [18]. According to one
estimate in England, by 2018, there will be 2.9 million people living with multimorbidity, as compared
with 1.9 million in 2008 [2].
Worldwide, prevalence ﬁgures for multimorbidity vary greatly depending on the type and the
number of conditions included [19,20]. In UK primary care, 16% of all adults were deﬁned with mul-
timorbidity using a total of 17 conditions then included in Quality and Outcomes Framework (QoF),
including asthma, atrial ﬁbrillation, cancer, coronary heart disease, chronic kidney disease, chronic
obstructive airways disease, dementia, depression, diabetes, epilepsy, heart failure, hypertension,
learning disability, mental health problem (psychosis, schizophrenia, or bipolar affective disorder),
obesity, stroke and thyroid disease. However, this deﬁnition did not include any MSDs and therefore
was likely to vastly underestimate the true prevalence of multimorbidity in primary care (QoF has since
been updated to include rheumatoid arthritis and osteoporosis). Unsurprisingly, the estimated prev-
alence increased to 58%when a broader list of long-term conditions was used, which included arthritis,
osteoporosis, gout and low back pain [11].
Because of their high prevalence, MSDs have higher odds of co-occurring with other long-term
conditions, therefore forming a component disorder in multimorbidity. In the European Union,
chronic musculoskeletal pain is experienced by an estimated 100 million people [21]. Back pain, for
example, has a mean estimated 1-year prevalence of 38%, worldwide [22]. Across the UK, an estimated
8.75million people have sought treatment for osteoarthritis, the equivalent to a third of all people over
45 years of age [23]. Additionally, an estimated 1 in 2 women aged over 50 years and 1 in 5 men will
sustain a low-trauma fracture as a result of osteoporosis [24e26], with the situation set to worsenwith
demographic changes [8]. The endemic high prevalence of these conditions is a key factor in explaining
their frequent contribution to multimorbidity.MSDs and multimorbidity share important risk factors
Many important risk factors for common MSDs show striking overlap with risk factors for multi-
morbidity, even where the deﬁnition of multimorbidity has not included MSDs. For example, age and
female gender are two of the most important non-modiﬁable risk factors for MSDs (though this may
not be true for individual conditions) [27]. Similarly, there is a greater risk of multimorbidity among
women than amongmen [28,29]. Unsurprisingly, multimorbidity is also associated with increasing age
[11,28]; the majority of people aged over 65 years are affected by multimorbidity [30]. For example, inPlease cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
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these rates increased to 81.5% among those aged 85 years or over [30].
Modiﬁable risk factors such as physical inactivity and obesity are importantly associated with
osteoarthritis and other regional pain syndromes, including low back pain [13]. Smoking is the main
modiﬁable risk factor for inﬂammatory arthritis, and lifestyle risk factors for osteoporosis include
smoking, poor nutrition and low physical activity [31]. Multimorbidity has a similarly clear association
with obesity [32e36], and while evidence about other modiﬁable risk factors for multimorbidity is
scarce, there are parallels with those for MSDs. For instance, smoking [34], physical activity in elderly
males [37] and nutrition [38] have been linked to multimorbidity in recent publications.
Social deprivation has been found to be associated with an increased likelihood of reporting chronic
painful conditions, including arthritis and back pain [39]. For example, among English people of
working age (45e64 years), the reported prevalence of arthritis was found to be more than double
(21.5%) that observed in the least deprived areas (10.6%) [40]. Multimorbidity also shows a strong
association with social deprivation [11,20,29]; people in the most deprived areas develop multi-
morbidity on average 10e15 years earlier than those living in the least deprived areas [30]. In
particular, a higher risk of multimorbidity including a mental health condition has been demonstrated
among people in the most deprived areas (11% versus 5.9%, respectively) [30].
MSDs and long-term conditions may cause and exacerbate one another
Lastly, sometimes there are direct causal relationships between MSDs and other long-term con-
ditions. For example, people with rheumatoid arthritis are at increased risk of developing several co-
morbid diseases including cardiovascular disease and osteoporosis because of shared aetiological
pathways. It has been estimated that one in 20 (6%) people with rheumatoid arthritis develops car-
diovascular disease, [41,42] while osteoporosis is present in three in 10 (30%) [43].
People with poor musculoskeletal health also carry a greater burden of mental health problems.
MSDs, like many long-term conditions, are associated with an increased risk of mood, anxiety and
substance use disorders. The association is even stronger in those with back pain or ﬁbromyalgia
[44,45]. MSDs and mental health have a complex and reciprocal relationship, each exacerbating, or
potentially causing, the other. Living with persistent pain can lead to depression and anxiety.
Conversely, psychological distress and depression worsen the experience and reporting of pain [46].
A cycle can therefore develop, with ever-worsening pain and low mood leading to social with-
drawal and isolation. People with mental health conditions may also delay seeking treatment, and
clinicians may underestimate physical symptoms, attributing these to an individual's mental health
condition [47].
MSDs and multimorbidity frequently occur together
A combination of the factors discussed above explains the high prevalence of MSDs found alongside
other long-term conditions as part of multimorbidity. For example, it has been shown that among
English primary care patients over 45 years of age, reporting living with a major long-term condition,
almost a third also have a musculoskeletal condition [40]. Moreover, among those aged >65 years,
almost half of thosewith a heart, lung or mental health problem, also had aMSD (see Fig. 1.) [40]. In the
most deprived populations, painful conditions such as osteoarthritis and back pain are the most
commonmultimorbidities among those already living with heart disease, diabetes, chronic obstructive
pulmonary disease (COPD) or cancer [30].
The converse is also true: people with a MSD have been shown to be more likely to have at least one
other long-term condition. For example, according to the results of one study, four out of ﬁve people
with osteoarthritis had at least one other long-term condition such as hypertension or cardiovascular
disease [6].
To visualise the relationship between MSDs and multimorbidity and recognise the varying multi-
morbidity criteria used in the literature, a recent cross-sectional study used three deﬁnitions to deﬁne
the prevalence of multimorbidity in working-age Australians. Two multimorbidity thresholds (i.e.
minimum of 2þ or 3þ conditions) and three deﬁnitions of multimorbidity from three sources werePlease cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
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Fig. 1. Prevalence of musculoskeletal disorders among English people (a) aged 45 years and over and (b) aged 65 years and over,
reporting other long-term conditions [40].
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deﬁnition from the Australian National Health Priority Areas and a research deﬁnition from a well-
cited systematic review. They found that irrespective of how multimorbidity is deﬁned, MSDs are a
near-ubiquitous feature of multimorbidity (see Fig. 2.) [4].Musculoskeletal diseases exacerbate the impact of multimorbidity
Having seen that MSDs are highly prevalent among people with multimorbidity, it is also important
to explore the contribution of MSDs to the total impact of multimorbidity. The personal, societal and
economic impact of MSDs and multimorbidity are outlined below.Please cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
multimorbidity: Implications for practice and policy, Best Practice & Research Clinical Rheumatology
(2017), https://doi.org/10.1016/j.berh.2017.09.004
Fig. 2. Overlap between Australian populations with MSDs and multimorbidity, as deﬁned by each deﬁnition and threshold. A total
working-age sample population; B sub-sample with at least one condition; C sub-sample with multimorbidity; D sub-sample with
any musculoskeletal condition; E musculoskeletal sub-sample considered multimorbid. Figure has been reproduced with permis-
sions from Lowe et al. (2017) [4].
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Worldwide, MSDs are the third largest cause of disability adjusted life years (DALYs) and the
largest single cause of years lived with disability (YLD) [48]. Pain is a very common feature of most
MSDs. For example, 78% of people with arthritis surveyed by Arthritis Research UK reported that they
experience pain most days, with 57% experiencing pain every day [49]. Activities of daily living (ADLs
or instrumental ADLs) such as bathing, dressing, getting out of bed or a chair, completing housework,
preparing meals and shopping are frequently affected by the pain, along with other common MSD
symptoms, such as stiffness, restricted mobility and impaired physical functioning [50]. People often
need to make adaptations to their home to enable them to cope. Moreover, symptoms of MSDs,
particularly those with an inﬂammatory cause, tend to ﬂuctuate in severity over time so that their
effects are unpredictable [51e53]. The pain, distress and functional limitations caused by MSDs
greatly reduce independence and quality of life and impair an individual's ability to participate in
family, social and working life [31]. Arthritis and back pain, in particular, are amongst the most
common causes of reduced health-related quality of life in the individual and, because of their high
prevalence, the wider population [29,46]. There is also a signiﬁcant impact on ﬁnancial health. Work
impairment and increased personal cost mean that 73% of people with severe arthritis struggle with
their ﬁnancial stability relative to their income, as compared with only 6% of those without functional
limitations [49].
People with multimorbidity are similarly less able to perform everyday tasks due to functional
decline [54]. People withmultimorbidity haveworsened quality of life and health outcomes than those
with one index condition [55]. For instance, in a range of index diseases, the presence of a co-morbidity
is consistently shown to increase mortality rates when compared to having the index disease alone
[55]. Morbidities tend to accrue in individuals, for instance, as the number of physical co-morbiditiesPlease cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
multimorbidity: Implications for practice and policy, Best Practice & Research Clinical Rheumatology
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pathologies contributes to the complex and numerous needs of people with multimorbidity.
Self-reported Quality of Life (QoL) scores can be used to understand the personal impact of long-
term conditions and can help to show the contribution of speciﬁc diseases to poor health in multi-
morbidity. In a national English survey, people living with one or more non-musculoskeletal long-term
conditions reported substantially poorer quality of life than those without a long-term condition (QoL
score 0.79 vs 0.90, respectively). However, quality of life was even more signiﬁcantly reduced among
those who had arthritis or back pain as part of their multimorbidity (QoL score 0.71). Notably, the
impact of the MSDs was signiﬁcant enough that living with arthritis or back pain resulted in impaired
quality of life irrespective of whether arthritis or back pain was the only condition (QoL score 0.68) or
was one among multimorbidity (QoL score 0.71) (see Fig. 3.). This suggests that MSDs dispropor-
tionately reduce quality of life in multimorbidity, compared to other long-term conditions [40].
MSDs contribute to the treatment burden in multimorbidity and can impair self-management, leading to
health and social decline
Despite the proven effectiveness of many individual therapies commonly used in long-termmedical
conditions, each additional therapy carries a ‘treatment burden’. Treatment burden is a concept that
encapsulates the physical effects of treatment, ﬁnancial losses and the psychosocial effects of time
demands and dependence on others for assistance [56]. Quite obviously, the effects of treatment
burden increase in a person receivingmultiple treatments for multiple health problems. For example, a
review of ﬁve UK disease-based clinical guidelines concluded that implementation of all individual
disease best practice recommendations for a person with multimorbidity would encourage poly-
pharmacy [57]. Recent clinical guidance recommends a person-centred approach to multimorbidity,
prioritising treatments that improve quality of life while minimising treatment burden [58].
The existence of any one MSD can contribute signiﬁcantly to the overall number of treatments a
person may be receiving. The management of MSDs aims to improve quality of life by reducing joint
pain and stiffness, limiting progression of joint damage, and maintaining or restoring functional ability
[59], but achieving this can necessitate the use of a range of interventions. This includes non-drug
interventions, e.g. physical activity, heat/cold or physiotherapy. Additionally, drug therapies for
MSDs may include topical or oral medication to ease joint pain and stiffness and reduce inﬂammation.
Amongst those severely affected, surgery may be required for people living in constant pain from
arthritis, e.g. osteoarthritis is responsible for over 90% of initial hip and knee joint replacements [60,61].0.90
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Fig. 3. Average Quality of Life scores for people aged 45 years and over who live with long-term conditions [40].
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maintain their health and administer their healthcare. This includes managing different tablets to be
taken at speciﬁc times of day, week or only occasionally; keeping stock of their pills, creams, inhalers
and injections; requesting repeat prescriptions on time; and visiting the pharmacy to collect items.
Monitoring of treatment effectiveness with regular blood tests or physical tests (e.g. blood pressure
measurement) may be required, and this may necessitate additional visits to the GP, or to the hospital
or may require an additional burden placed upon the individual (e.g. self-monitoring of blood glucose
in diabetes mellitus) [56]. As health systems are largely conﬁgured to treat individual diseases rather
than support those living with multimorbidity [30], managing multiple long-term conditions may
require the attention of an array of separate health and care professionals at home, in the community
and in hospitals. The time and effort required to remember and attend these appointments (including
travel time and car parking or negotiating with hospital transport) contributes to the treatment
burden [56].
Having a musculoskeletal condition as part of multimorbidity makes all of these activities more
difﬁcult. The Centres for Disease Control and Prevention's (CDC) Arthritis Program in the USA has
identiﬁednine functional limitations that peoplewith arthritis report as being ‘verydifﬁcult’or that they
‘cannot do’, including grasping small objects, lifting or carrying, prolonged sitting or standing,walking a
quarter mile, climbing stairs, and stooping, bending or kneeling [62]. As a result, co-morbid arthritis or
back pain substantially restricts the function and daily activities of people living with cardiovascular
disease, diabetes and respiratory disease [63]. In addition, the unpredictable ﬂuctuations in symptom
severity that are a frequent feature of MSDs restrict mobility and can make attending hospital or GP
appointments and planning ahead difﬁcult, directly limiting people's ability to manage their health.
The personal expense of MSDs treatment should not be ignored either because these costs may
mean that a person with multiple long-term conditions will not be able to afford all their own treat-
ments, leading to deterioration in health. In the United States, osteoarthritis was found to contribute
substantially to healthcare insurance expenditures, especially amongwomen. Additional out-of-pocket
expenditures were also increased by $1379 per annum in women and $694 per annum in men with
osteoarthritis, a substantial personal cost [64]. Nearly half the people with arthritis surveyed by
Arthritis Research UK (48%) reported that they could not afford all the treatments they wanted or
needed, and this ﬁgure increased to nearly 8 out of 10 (78%) among those who stated that they were
‘struggling ﬁnancially’ [49].
Therefore, for a person who is just managing despite their multiple long-term conditions, devel-
oping arthritis can take away their ability to cope with, or afford, treatment. This may prevent effective
self-management for other long-term conditions, which could then worsen. For example, people with
painful osteoarthritis alongside their other long-term conditions have been shown to have increased
risk of needing hospital admission [65]. Therefore, the onset of arthritis may be a ‘tipping point’ for
people with multimorbidity, depriving people of their ability to maintain their health and indepen-
dence, leading to a spiral of decline.
MSDs contribute to the impact of multimorbidity on health and care services
Management for people with multimorbidity should follow a person-centred, biopsychosocial
approach incorporating the six desirable elements of care identiﬁed by people with long-term con-
ditions (see Fig. 4) [66]. These elements can be enabled through systems to support self-management
and shared decision-making and the implementation of care and support planning (see Table 1).
However, these systems can be time and resource intensive because of the complexity of the care
needed and are increasingly stretched because of the growing number of individuals who need such
services. For example, UK health and social care costs average nearly £8000 per year to care for a person
living with three or more long-term conditions as compared with an estimated £3000 for a person
living with only one long-term condition [2].
The high prevalence and complexity of needs among people with MSDs is likely to contribute
heavily to the overall cost of multimorbidity as MSDs carry their own innate burden on health and care
services. The Ontario Health Survey, in Canada, found that MSDs were the reason for almost 20% of all
healthcare utilisation [67]. In 2015 alone, there were more than 98,211 primary hip replacements andPlease cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
multimorbidity: Implications for practice and policy, Best Practice & Research Clinical Rheumatology
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Fig. 4. A narrative for person-centred coordinated care [66].
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cidences of hip fractures, requiring emergency surgery, vary but amount to 9 to 11 per 10,000 person-
years in the general population [69]. Moreover, because MSDs are usually life-long conditions, people
with arthritis may need health and care services for many decades. In England, managing these con-
ditions accounts for the fourth-largest National Health Service (NHS) programme budget of around
£5.3 billion annually [70]. In the European Union, it is estimated that 2% of the total annual gross
domestic product (GDP) is accounted for by the direct costs of MSDs [71].
In English primary care, people with multimorbidity are frequent users of services [72]: whilst six
out of 10 (58%) patients have multimorbidity, they account for almost eight out of 10 (78%) of the
consultations in primary care [11]. People with multimorbidity average nine consultations each year
compared to four consultations for those without [11]. MSDs contribute importantly to the healthcare
burden because one in ﬁve of the general population consults their general practitioner (GP) about
MSDs annually [73], and MSDs account for one in eight (12%) of all appointments in primary care [74].
Similar estimated rates of consultation have also been reported in other countries, where 10e20% of
primary care consultations are for MSDs [75].
The presence of multimorbidity also comes with an increased risk of hospitalisation [76e78] and
hospital outpatient visits [72]. Once in hospital, people being treated for one condition may have otherTable 1
Key management strategies for people with multimorbidity.
Supported self-
management
National guidelines recommend that people living with multimorbidity should be supported to manage
their own health and wellbeing and given shared responsibility for this with their healthcare
professionals [81]. A person's ability to do this is affected by their symptoms, treatments and the
required administration to implement management. ‘Patient activation’ is a measure of a person's skill,
knowledge, and conﬁdence to manage their health and healthcare [82]. Low levels of activation have
been linked to increased risk of hospitalisation and use of emergency services [83].
Shared decision-
making support
Shared decision-making is a process in which people can review all the treatment options available to
them and participate actively with their healthcare professional in making that decision [84]. People
living with multiple, long-term health conditions should be equal participants in decisions about their
health and social care needs [81]. Decision aids can be used either before or during consultations to
review options to help the person and the health or care professional explore options [85]. Use of these
aids improves how well informed and active in decision-making a patient feels and gives a more
accurate perception of risk [86].
Care and support
planning
Care and support planning comprises a collaborative, personalised care planning conversation usually
occurring between a person with one or more long-term conditions and a healthcare professional. UK
guidelines recommend that this conversation should bring together information gathered by the
healthcare professional and the goals, values and priorities of the person with the condition, allowing
time to develop and record a care and support plan [81]. This is also a multi-stage process, so
information such as test results can be shared in advance, allowing the person time to consider their
priorities and consult their family or carers if they wish [87].
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morbidities increases the 30-day mortality risk of people following hip fracture surgery [79]. Osteo-
porosis leading to fragility fractures is the major cause of fractures; however, incidence rates of fracture
are inﬂuenced by fall risk-related co-morbidities such as heart disease, COPD and dementia [80].
Therefore, multimorbidity and MSDs, together, can magnify the total burden in secondary care.
MSDs contribute to the impact of multimorbidity in the workforce and the economy
The physical limitations associated with MSDs have a widely acknowledged impact upon work:
people with MSDs are less likely to be employed than people in good health and are more likely to
retire early [88]. In the European Union and the United States, MSDs are reported to account for a
higher proportion of sickness absence from work than any other health condition [21,89]. In England,
people with a MSD have the third lowest rate of full-time paid work (see Fig. 5.) and are the third
highest reported reason for being permanently sick or disabled, after mental health conditions or a
recent cancer experience [40]. The indirect costs (inability to work, absenteeism, reduced productivity
and informal care) of rheumatoid arthritis and osteoarthritis combined have been estimated at £14.8
billion each year [90]. According to another estimate, back pain is responsible for £10 billion of indirect
costs to the economy each year [91].
Individually, MSDs andmental health problems are the two biggest causes of the greatest number of
working days lost in England [92]. However, these types of conditions frequently occur together. For
example, around three in 10 (32%) people of working age who have a musculoskeletal condition also
have depression [93]. People with a co-morbid mental health problem alongside a MSD are less likely
to be in work than those with musculoskeletal conditions alone [93].
Evidence on the impact of multimorbidity on work outcomes is scarce and often restricted to the
study of two speciﬁc diseases combined [5]. However, the presence of multimorbidity, and the number
of chronic conditions, has been correlated with work absence [94e97] and reduced work productivity,
also known as presenteeism [94,95]. The impact of multimorbidity on job status and work absence has
also been shown to incrementally worsen with each additional condition [5].
Importantly inmultimorbidity, it has been shown that the type of long-term conditions, and not only
number of long-term conditions, is associated with work outcomes [95]. Therefore, given the44.5%
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overall impact of multimorbidity upon work. To illustrate this, one study showed that the effect of
multimorbidity uponwork disability, sickness leave and job status is signiﬁcantly ampliﬁedwhenMSDs
are included in the deﬁnition ofmultimorbidity [5]. This suggests thatMSDs should not be omitted from
any studies examining, or adjusting for, the impact of multimorbidity in work participation.
Implications for practice and policy
The Chief Medical Ofﬁcer for England has acknowledged osteoarthritis as ‘an unrecognised public
health priority’ [98]. People with arthritis have also drawn attention to the lack of recognition of their
condition within healthcare services and across society [49]. This lack of recognition may be due to a
focus on conditions with higher mortality rates rather than those which primarily increase morbidity
and reduce quality of life, due to the nihilistic perception that nothing can be done for people with
MSDs and that arthritis is an inevitable part of ageing, or due to difﬁculties measuring musculoskeletal
health outcomes because of a lack of biomarkers or simple tests to monitor musculoskeletal health.
Goodmusculoskeletalhealthunderpins independent livingwithmultiple long-termconditions. Itmust
thereforeﬁrstly be recognised and addressed as part ofmultimorbidity.MSDs negatively impactonquality
of life [40], functional ability [63], risk of hospitalisation [65], and work disability [5] in multimorbidity.
Metrics and tools developed for multimorbidity management programmes should therefore monitor
outcomes that are relevant tomusculoskeletal health, including pain and its impact, and functional ability.
We suggest that high-quality data on MSDs and multimorbidity should be routinely obtained,
published and used across public health, health and care, and other related systems. These data should
identify the scale and needs of people with multimorbidity and support service delivery and quality
improvement activities. Currently, routinely collected data sometimes overlooks the co-existence of
MSDs, leading to substantial under-estimates of multimorbidity prevalence, let alone their impact.
Local government and public health teams along with healthcare commissioners, payers and
providers should identify, segment and understand the needs and requirements of people living with
MSDs and multimorbidity in their population. They should identify barriers, including physical bar-
riers, that could limit the access of people with arthritis and MSDs to local programmes. To date, this
has been poorly achieved, at least in England, for osteoarthritis and back pain [99].
People withmultimorbidity should have access to person-centred, integrated services. For example,
care and support planning should be offered to anyone with a long-term condition [100], but partic-
ularly to people with multimorbidity [58]. There must be clarity about who will be responsible for
carrying out the different actions outlined in a plan, with appropriate support and coordination to link
to local services [101]. When supporting people with multimorbidity to identify health goals, pro-
fessionals should ensure that people have the information they need to make decisions about
improving their musculoskeletal health.
Public health information, programmes and campaigns should recognise and address the needs of
the growing numbers of people living with multimorbidity and MSDs. The impact of pain and func-
tional limitations on physical activity and independence should be taken into consideration when
designing, implementing and evaluating public health information, programmes and campaigns.
Disease-speciﬁc non-proﬁt organisations and coalitions should recognise the prevalence of multi-
morbidity and work together to develop relevant resources, programmes, research and partnerships to
meet the changing needs of their beneﬁciaries. Non-proﬁt organisations should also collaborate with
service providers to identify ways of working thatmeet the needs of people living withmultimorbidity,
including developing policy, providing information and support, and delivering models of care. In the
UK, the non-proﬁt sector is a substantial contributor to health and care support with nearly 36,000
health and social care organisations spending around £4,522million directly supporting people, health
systems or care systems in 2013/14 [102]. This capacity should be harnessed to meet the needs of
people with multimorbidity.
Lastly, we suggest that funders must extend support for research to improve understanding of
multimorbidity and to develop and evaluate strategies to meet the needs of people with multi-
morbidity. Organisations that historically have focussed on single disease areas should explore ways to
collaborate on multimorbidity research. Facilitation for cross-sector collaborations can come fromPlease cite this article in press as: Dufﬁeld SJ, et al., The contribution of musculoskeletal disorders in
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which, in 2015, issued a research call for evaluation of interventions or services for older people with
multimorbidity [103]. Examples of current multimorbidity research include the 3D study, which is
developing and testing a comprehensive ‘3D’ health review every 6 months for people with multi-
morbidity in general practice [104], and the HEAF study, which is measuring the impact of common
health conditions and multimorbidity on work capability and work participation at older age [105].
Summary
MSDs such as arthritis or back pain are common and cause pain, stiffness, reduced mobility and
dexterity, and depression. These symptoms affect every aspect of life: family, work and social.
It is now common for people to live with two or more long-term conditions. This multimorbidity
reduces quality of life, worsens health outcomes and increases mortality. People with multimorbidity
also rely more heavily on health and care services.
People living with multimorbidity often have a MSD as one of their health problems. Living well
with multimorbidity involves a litany of complex tasks: monitoring symptoms, managingmedications,
coordinating carers and attending appointments. The pain and functional limitations associated with
arthritis can make taking treatments, getting to appointments and co-ordination of care harder.
Therefore, the onset, or worsening, of arthritis or back pain can completely undermine people's ability
to cope with their health problems and manage their multimorbidity independently, leading to a
precipitous deterioration in health and work-life.
We believe that there is compelling evidence that policymakers, charities and research funders
should recognise musculoskeletal health as part of multimorbidity. Consideration and assessment of
pain and functional abilities should be included in tools and interventions to identify and support
people with multimorbidity. Musculoskeletal health data should be captured and its quality improved;
this information should be used in multimorbidity analyses and planning. Healthcare professionals
should consider and discuss pain and functional limitations in their care and support planning con-
versations. Lastly, other professionals and the public should be educated to consider musculoskeletal
health as part of multimorbidity through relevant public health resources.Practice points
 Identification: Metrics and tools developed for multimorbidity management programmes
should monitor and measure pain and its impact, functional abilities, and capability to
manage.
 Data collection:National bodies shouldwork together to ensure that data collection, analysis,
and publication raises awareness of multimorbidity and the relevance of its musculoskeletal
component.
 Planning and commissioning: Local planners and commissioners of health and care services
should identify, segment and understand the needs and requirements of people living with
musculoskeletal disorders and multimorbidity in their populations. This information should
be collected and published where possible.
 Care and support planning: Health and care professionals should ensure that people with
multimorbidity can take part in a care and support planning process. This should use
standardised tools to explore and record pain, functional limitations, and how these affect
daily activities. Other aspects of patient-centred care, such as shared decision-making,
should be an integral part of this process.
 Health promotion: Public health organisations should ensure that their information, pro-
grammes, and campaigns reflect and address the needs of the growing numbers of people
living with multimorbidity including musculoskeletal disorders.
 Voluntary sector: Disease-specific non-profit organisations and their respective coalitions
should recognise that many people now live with multimorbidity and work together to
develop resources, programmes, research, and partnerships. This shared work should aim to
meet the changing needs of people with multiple long-term conditions.
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Research agenda
 Prevalence: Robust surveillance systems should be developed and validated for monitoring
multimorbidity prevalence, along with its component diseases, which should include
musculoskeletal disorders.
 Impact of multimorbidity:More data is needed to define the impact of multimorbidity, and its
contributory diseases (including musculoskeletal disorders), on health, healthcare systems,
society, and work.
 Models and pathways of care: Interventions, systems, and management strategies to sup-
port people with multimorbidity to live well should be designed, tested, and scaled up.
 Outcome measures: Standardised outcome measures should be developed, validated,
implemented, analysed, and interpreted for people with multimorbidity, including muscu-
loskeletal disorders.
 Individual perspectives:New research should seek to understand how the attitudes of people
and healthcare professionals towards multimorbidity affect health outcomes.
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